Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBT Margin (2016 - 2025)

Zevra Therapeutics' EBT Margin history spans 9 years, with the latest figure at 37.08% for Q4 2025.

  • For Q4 2025, EBT Margin rose 20638.0% year-over-year to 37.08%; the TTM value through Dec 2025 reached 81.35%, up 46370.0%, while the annual FY2025 figure was 81.39%, 46334.0% up from the prior year.
  • EBT Margin reached 37.08% in Q4 2025 per ZVRA's latest filing, up from 3.74% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 296.93% in Q2 2025 to a low of 5405.69% in Q3 2022.
  • Average EBT Margin over 5 years is 505.11%, with a median of 96.44% recorded in 2021.
  • Peak YoY movement for EBT Margin: tumbled -531617bps in 2022, then surged 505370bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 103.37% in 2021, then surged by 71bps to 30.09% in 2022, then crashed by -412bps to 153.96% in 2023, then decreased by -10bps to 169.3% in 2024, then surged by 122bps to 37.08% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EBT Margin are 37.08% (Q4 2025), 3.74% (Q3 2025), and 296.93% (Q2 2025).